Floatz logo

AMIFAMPRIDINE

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

National Center for Research Resources (NCRR)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Chronic Inflammatory Demyelinating Polyradiculoneuropathy cohort.

Asset / SponsorPhaseRating
HUMAN IMMUNOGLOBULINS
National Center for Research Resources (NCRR)
Phase 3BB
i10e
Laboratoire français de Fractionnement et de Biotechnologies
Phase 3B
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2CCC
Camustine
Fred Hutchinson Cancer Center
Phase 2CCC
MELPHALAN
Fred Hutchinson Cancer Center
Phase 2CCC

View all 18 →

Same molecule, other indications

AMIFAMPRIDINE is also rated in:

multiple sclerosisDormant
B
Indicative · Phase 3
59 / 100
View asset →
spinal muscular atrophyDormant
B
Indicative · Phase 2
57 / 100
View asset →
spinal muscular atrophy, type IIIDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →